An interventional study of Enhanced Fat Grafting and Standard fat graft in Wounded Warrior, Limb Shortening and Amputation, sponsored by J. Peter Rubin, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-10.
Sponsored by J. Peter Rubin, MD · Not applicable, Interventional, and Basic science
We propose a prospective, randomized clinical study to assess the efficacy of minimally invasive autologous fat transfer addressing pain and poor prosthetic fit at amputation sites.
We hypothesize that autologous fat grafting can provide a minimally invasive therapy facilitated by enabling technology of specialized instrumentation to effectively mitigate pain syndromes at amputation sites, by introducing volume stable subcutaneous tissue over bony prominences and peripheral nerve trunks, thereby avoiding surgical revisions and preserving limb length.
We further hypothesize that enriching the fat graft with autologous adipose stromal cells utilizing the Tissue Gensis Cell Isolation System (CIS), a regenerative medicine approach, will lead to improved retention of the fat graft over time and result in a more favorable outcome.
Specific Aims:
Study Design:
Single center site, prospective, randomized, pilot outcomes study with treatment performed at the University of Pittsburgh.
The primary outcome measurements will be: 1) fat graft retention at the amputation site; and 2) improved ability to tolerate a prosthetic device. This study will examine if fat grafting with cell enrichment using the Tissue Gensis Cell Isolation System, (CIS) will demonstrate increased fat retention and decreased pain compared to standard fat grafting alone.
Clinical Impact:
This study will significantly impact military trauma care by validating a minimally invasive cell based technique for alleviating pain at amputation sites and improving function with a prosthesis. Importantly, the goal will be reached without invasive surgery, increased risk, and a prolonged recovery. Given the high amputation rate in the current conflicts, this work is highly relevant to the care of the wounded warrior. A major goal of this study will be to transfer the techniques and knowledge gained to physicians throughout the Department of Defense healthcare system.
J. Peter Rubin, MD is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Once harvested the aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
Procedure: Standard fat graft
Approximately 60 cc of lipoaspirate will be collected from the subject to be processed with the Tissue Genesis Cell Isolation System™ (CIS) to yield approximately 35cc of Stromal Vascular Fraction (SVF).Once harvested the aspirated fat will then be divided into two portions: one portion will be processed as standard graft material (standard/control graft) while the other portion will be used in a processing step that concentrates the adipose stromal cells. The aspirated fat processed as standard graft material will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and allowed to decant before separating the fluid and oil layers from the fat tissue fractions, and transferred into 50 ml syringes. This graft preparation will be performed in the operating room.
Device: Enhanced Fat Grafting
The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™ The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity. To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject.
Also known as: Tissue Genesis Cell Isolation System™ (CIS)
Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
Efficacy of Autologous Fat Transfer at Pain Modulation at Respective Amputation Sites
Assess the efficacy of minimally invasive autologous fat transfer at the amputation sites and the modulation of pain at the respective sites Compare two minimally invasive techniques as an alternative to invasive operations, with the understanding that this therapy does not preclude more invasive procedures in the future. We further hypothesize that enriching the fat graft with autologous adipose stromal cells utilizing the Tissue Genesis Cell Isolation System (CIS), a regenerative medicine approach, will lead to improved retention of the fat graft over time and result in a more favorable outcome. Subjects reported pain on a scale of 0-5 where 5 was the worst pain and 0 was no pain.
Time frame: 2 years
Cell Yield
To assess biologic properties of the cells within the fat graft, we evaluated adipose stem cell viability by multiparameter flow cytometry.
Time frame: day 0
Number of Participants With Clinically Significant Levels of Depression on the Patient Health Questionnaire-9 (PHQ-9)
Measure quality of life in patients before and after autologous fat grafting using validated psychosocial measures. This will evaluate using instruments designed for assessing depression including the Patient Health Questionnaire-9 (PHQ-9) which is a tool to screen, diagnose, monitor, and measure the severity of depression.
Time frame: 2 years
| Milestone | Standard Fat Grafting | Enhanced Fat Grafting |
|---|---|---|
| Started | 7 | 3 |
| Completed | 5 | 3 |
| Not completed | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
Assess the efficacy of minimally invasive autologous fat transfer at the amputation sites and the modulation of pain at the respective sites Compare two minimally invasive techniques as an alternative to invasive operations, with the understanding that this therapy does not preclude more invasive procedures in the future. We further hypothesize that enriching the fat graft with autologous adipose stromal cells utilizing the Tissue Genesis Cell Isolation System (CIS), a regenerative medicine approach, will lead to improved retention of the fat graft over time and result in a more favorable outcome. Subjects reported pain on a scale of 0-5 where 5 was the worst pain and 0 was no pain.
| score on a scale | Standard Fat Grafting | Enhanced Fat Grafting |
|---|---|---|
| Efficacy of Autologous Fat Transfer at Pain Modulation at Respective Amputation Sites | 1.3 ± 1 | 0 ± 0 |
To assess biologic properties of the cells within the fat graft, we evaluated adipose stem cell viability by multiparameter flow cytometry.
| percentage of SVF cell viability | Standard Fat Grafting | Enhanced Fat Grafting |
|---|---|---|
| Cell Yield | 69.9 ± 31.8 | 82.7 ± 3.6 |
Measure quality of life in patients before and after autologous fat grafting using validated psychosocial measures. This will evaluate using instruments designed for assessing depression including the Patient Health Questionnaire-9 (PHQ-9) which is a tool to screen, diagnose, monitor, and measure the severity of depression.
| Participants | Standard Fat Grafting | Enhanced Fat Grafting |
|---|---|---|
| Number of Participants With Clinically Significant Levels of Depression on the Patient Health Questionnaire-9 (PHQ-9) | 0 | 0 |
Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard Fat Grafting | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Enhanced Fat Grafting | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Standard Fat Grafting | Enhanced Fat Grafting |
|---|---|---|
| Bruising at donor siteSurgical and medical procedures | 7/7 | 3/3 |
| Age, Continuous(years) | Standard Fat Grafting | Enhanced Fat Grafting | Total |
|---|---|---|---|
| Mean | 56.3 ± 13.0 | 46.4 ± 18.1 | 49.9 ± 16.7 |
| Sex: Female, Male(Participants) | Standard Fat Grafting | Enhanced Fat Grafting | Total |
|---|---|---|---|
| Female | 3 | 0 | 3 |
| Male | 4 | 3 | 7 |
| Race (NIH/OMB)(Participants) | Standard Fat Grafting | Enhanced Fat Grafting | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 7 | 2 | 9 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Standard Fat Grafting | Enhanced Fat Grafting | Total |
|---|---|---|---|
| United States | 7 | 3 | 10 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — It is the Principal Investigator's intention to make subject de-identified information available to secondary investigators after all research study testing has been completed. These associated subject information will not include subject identifiers.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
J. Peter Rubin, MD